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Abstract: In this diagnostic test validation study, we assessed the clinical accuracy and HPV
genotyping performance of the INNO-LiPA HPV Genotyping Extra II (INNO-LiPA) within the
VALGENT-3 framework. VALGENT is designed to assess the analytical and clinical performance of
HPV tests with genotyping capacity. The VALGENT-3 panel comprised 1300 consecutive cervical cell
specimens enriched with 300 samples with abnormal cytology obtained from women attending the
Slovenian cervical cancer screening programme. The INNO-LiPA allows type-specific detection of
32 HPV types; however, for the clinical accuracy assessment, we considered it as high-risk (hr)HPV
positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33,
HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and HPV68. Clinical accuracy
for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was compared between
INNO-LiPA and Hybrid Capture 2 (HC2), which is a standard comparator test for HPV tests used in
cervical cancer screening. In addition, hrHPV and type-specific detection HPV types were compared
between INNO-LiPA and Linear Array HPV Genotyping Test (Linear Array). The prevalence of
hrHPV determined by INNO-LiPA was 17.1% (95% CI, 15.0–19.2%) in the screening population.
HrHPV testing with INNO-LiPA had a sensitivity for CIN2+ of 96.9% (95% CI, 92.1–99.1%) which
was non-inferior to HC2 (relative sensitivity of 1.01; 95% CI, 0.97–1.04; pn.inf = 0.0002) and a specificity
for ≤CIN1 of 85.3% (95% CI, 83.2–87.3%) which was inferior to HC2 (relative specificity of 0.95;
95% CI, 0.93–0.97; pn.inf = 0.9998). Genotyping agreement between INNO-LiPA and Linear Array
was excellent for hrHPV, HPV16, HPV18, HPV35, HPV45, HPV58 and HPV59, but good or fair for
other HPV types. To conclude, INNO-LiPA demonstrated non-inferior clinical sensitivity but lower
specificity compared to HC2 in addition to excellent concordance compared to Linear Array for
hrHPV and some genotypes.
Keywords: INNO-LiPA; VALGENT; HPV genotyping; cervical cancer; human papillomavirus;
clinical validation; Hybrid Capture 2; Linear Array
1. Introduction
Over 200 human papillomavirus (HPV) types have been identified and classified based on their
nucleotide sequences, with new HPV types being characterized at an increasing rate [1]. Among them,
12 high-risk HPV (hrHPV) types (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51,
HPV52, HPV56, HPV58 and HPV59) are causally linked with cervical cancer and their immediate
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precursors [2]. In addition, eight more HPV types have been associated with some rare cases of cervical
cancer (HPV26, HPV53, HPV66, HPV67, HPV68, HPV70, HPV73 and HPV82) [3]. The recognition
of the strong etiological association between persistent hrHPV infection and cervical cancer has led
to the development of novel HPV tests to enhance secondary prevention of the cervical cancer [4,5].
Furthermore, randomized controlled trials (RCTs) have demonstrated that HPV-based screening is
more effective than cervical cytology in reducing the incidence of invasive cervical carcinoma in
primary screening for cervical cancer for women aged 30 years or older [5,6]. Thus, a number of
countries are currently in the process of switching from cervical cytology to HPV based primary
screening for cervical cancer [7].
Many HPV tests are available on the market but only few have been clinically validated
for use in primary screening settings [8]. The Hybrid Capture 2 assay (HC2; Qiagen, Hilden,
Germany) [6,9–11] and GP5+/6+ PCR-based enzyme immunoassay (GP5+/6+-EIA; Diassay, Rijwijk,
the Netherlands) [12–14] are HPV DNA assays that had been clinically validated for primary screening
based on longitudinal evidence obtained from large RCTs. Therefore, HC2 and GP5+/6+-EIA are
accepted as the standard comparator tests in evaluations of alternative HPV tests [15]. Several other
HPV tests have been fully or partially validated and demonstrate non-inferior clinical sensitivity and
specificity for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) compared to
the standard comparator tests and high inter-and intra-laboratory reproducibility [15,16]. Majority
of validated HPV tests target 13 or 14 hrHPV types in aggregate, but some have limited (partial
genotyping for HPV16 and HPV18 only), extended (separate genotyping of HPV16, HPV18 and
other hrHPV types) and full (type-specific genotyping of all included types) genotyping ability [16].
Since HPV16 and HPV18 are responsible for approximately 70% of cervical cancer, partial HPV
genotyping for these two types is frequently used in the triage of HPV-positive women [17,18].
Although the usefulness of full genotyping of hrHPV types is not yet established, a recent study
showed that, in addition to HPV16, HPV31 and HPV33 are more carcinogenic than other hrHPV types,
suggesting that wider genotyping may also be clinically valuable [19].
INNO-LiPA HPV genotyping assay, based on the principle of reverse hybridization after highly
sensitive PCR amplification with SPF10 primers, have been used for HPV genotyping over two
decades [20,21]. During this timeframe, the original assay has undergone several modifications,
resulting in a few different versions. The INNO-LiPA HPV Genotyping Extra II assay (INNO-LiPA;
Fujirebio Europe, Ghent, Belgium) evaluated in the current study is the most recent assay launched by
the company in 2015, targeting 32 types, four types more than the previous version. This new version
contains genotype specific probes for more decisive genotyping results, an upgraded SPF10 primer set
resulting in improved sensitivity (comparable for all hrHPV types), improved human DNA control
primers and provides a ready-to-use amplification reagent [22].
In the present study, the VALidation of HPV GENotyping Tests (VALGENT) framework was used
to evaluate the clinical accuracy of INNO-LiPA in comparison with HC2. For the first time, it was
verified whether hrHPV testing with INNO-LiPA fulfills the minimal requirements for use in primary
cervical cancer screening [15]. In addition, type-specific concordance was compared between the
INNO-LiPA and the Linear Array HPV Genotyping Test (Linear Array; Roche Molecular Diagnostics,
Branchburg, NJ, USA). HrHPV testing with the latter test was recently clinically validated through
the VALGENT network as well and has been proposed as a standard analytical HPV genotyping
comparator test to resolve discordant typing results of clinically validated HPV assays [23].
2. Results
The characteristics of the VALGENT-3 study population, including demographics, cytological
and histological results have been described previously [23,24]. Of the 1600 samples analyzed by
INNO-LiPA, four samples showed no signal for human HLA-DPB1 gene control line. These four
samples were considered as invalid and therefore excluded for further analysis. Of the 1296 valid
samples obtained from screening population, 17.1% women (221/1296) tested positive for the presence
Int. J. Mol. Sci. 2018, 19, 2704 3 of 11
of any of the 13 hrHPV types by INNO-LiPA. The overall and type-specific prevalence of 13 hrHPV
types in the total study population determined by INNO-LiPA is summarized in Table 1. The hrHPV
prevalence was 15.2% in women with NILM (negative for intraepithelial lesion or malignancy) and
increased to 42.8%, 69.0% and 86.0% in women diagnosed with ASC-US (atypical squamous cells of
undetermined significance), LSIL (low-grade squamous intraepithelial lesion) and HSIL(high-grade
squamous intraepithelial), respectively. The risk ratio (RR) of HSIL compared to women with NILM
was highest (RR > 8.00) in women infected with in HPV16, HPV33, HPV18 and HPV45.
Table 1. Overall prevalence of hrHPV (aggregate of 13 types) and of individual hrHPV types detected
by INNO-LiPA in the total study population according to baseline cytology.
HPV Type
HrHPV Prevalence (No. and %) by Cytology Results Ratio PrevalenceHSIL/NILM
NILM
(N = 1234)
ASC-US
(N = 131)
LSIL
(N = 113)
HSIL
(N = 114)
13 hrHPV * 187 (15.2%) 56 (42.8%) 78 (69.0%) 98 (86.0%) 5.7
HPV16 32 (2.6%) 12 (9.2%) 27 (23.9%) 56 (49.1%) 18.9
HPV18 12 (1.0%) 4 (3.1%) 9 (8.0%) 10 (8.8%) 8.8
HPV31 54 (4.4%) 22 (16.8%) 19(16.8) 23 (20.2%) 4.6
HPV33 11 (0.9%) 5 (3.8%) 9 (8.0%) 11 (9.7%) 10.8
HPV35 3 (0.2%) 1 (0.8%) 0 (0.0%) 2 (0.9%) 4.5
HPV39 16 (1.3%) 1 (0.8%) 5 (4.4%) 2 (1.8%) 1.4
HPV45 6 (0.5%) 5 (3.8%) 4 (3.5%) 5 (4.4%) 8.8
HPV51 31 (2.5%) 4 (3.1%) 9 (8.0%) 5 (4.4%) 1.8
HPV52 27 (2.2%) 10 (7.6%) 11 (9.7%) 7 (6.1%) 2.8
HPV56 11 (0.9%) 2 (1.5%) 7 (6.2%) 5 (4.4%) 4.9
HPV58 9 (0.7%) 3 (2.3%) 7 (6.2%) 5 (4.4%) 6.3
HPV59 11 (0.9%) 3 (2.3%) 4 (3.5%) 0 (0.0%) 0
HPV68 16 (1.3%) 5 (3.8%) 7 (6.2%) 5 (4.4%) 3.4
NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined
significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial.
* A positive hrHPV result represents detection of at least one of the 13 hrHPV types included in the HC2: HPV16,
HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59 and HPV68. Women
infected with multiple HPV types were counted only once.
2.1. Clinical Performance of the INNO-LiPA
The accuracy data for the INNO-LiPA and HC2 for the outcomes CIN2+, CIN3+ and ≤CIN1 are
shown in Table 2 for the total study population and for women aged 30 years or older. When the
whole study population was considered, INNO-LiPA detected 123 of 127 CIN2+ cases and 81 of 82
CIN3+ cases, which corresponds to a sensitivity of 96.9% (95% CI, 92.1–99.1) and 98.8% (93.4–100),
respectively. The specificity for ≤CIN1 of INNO-LiPA (1034/1212) was 85.3% (95% CI, 83.2–87.3).
Similar results were obtained for women aged 30 years or older.
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Table 2. Sensitivity of INNO-LiPA and HC2 for detection of CIN2+ and CIN3+ and specificity of both
assays for detection of ≤CIN1. Analysis was performed separately for the total study population and
for women ≥30 years old.
Assay, Study Population and
Clinical Outcome
Sensitivity Specificity
n/N % 95% CI n/N % 95% CI
INNO-LiPA a
Total study population
CIN2+ 123/127 96.9 (92.1–99.1)
CIN3+ 81/82 98.8 (93.4–100)
≤CIN1 1034/1212 85.3 (83.2–87.3)
Women >30 years old
CIN2+ 95/98 96.9 (91.3–99.4)
CIN3+ 65/66 98.5 (91.8–100)
≤CIN1 887/1009 87.9 (85.7–89.9)
HC2
Total study population
CIN2+ 122/127 96.1 (91.1–98.7)
CIN3+ 80/82 97.6 (91.5–99.7)
≤CIN1 1092/1212 90.1 (88.3–91.8)
Women >30 years old
CIN2+ 94/98 95.9 (89.9–98.9)
CIN3+ 64/66 97.0 (89.5–99.6)
≤CIN1 935/1009 92.7 (90.9–94.2)
a Positive INNO-LiPA results represents detection of at least one of the following 13 hrHPV types included in
the HC2: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59 and
HPV68. n, number of cases; N, total number of cases; CI, confidence interval.
The relative sensitivity of INNO-LiPA compared to HC2 was 1.01 (95% CI, 0.97–1.04; pmcn = 0.6547;
pn.inf = 0.0002) for CIN2+ and 1.01 (95% CI, 0.97–1.06; pmcn = 0.5637; pn.inf = 0.001) for CIN3+.
The relative specificity of INNO-LiPA for ≤CIN1 was 0.95 (95% CI, 0.93–0.97; pmcn = 0.0000;
pn.inf = 0.0000). Similar results were obtained if the analysis was restricted to women ≥30 years
(Table 3).
Table 3. Relative sensitivities for detection of CIN2+ and CIN3+ and relative specificity for detection of
≤CIN1 of INNO-LiPA versus HC2. Analysis was performed separately for the total study population
and for women ≥30 years old.
INNO-LiPA vs. HC2 Relative Sensitivity Relative Specificity pmcn a pn.inf b
Total study population
CIN2+ 1.01 (0.97–1.04) 0.6547 0.0002
CIN3+ 1.01 (0.97–1.06) 0.5637 0.001
≤CIN1 0.95 (0.93–0.97) <0.001 0.9998
Women > 30 years old
CIN2+ 1.01 (0.96–1.06) 0.6547 0.001
CIN3+ 1.02 (0.96–1.07) 0.5637 0.003
≤CIN1 0.95 (0.93–0.97) <0.001 0.999
a p for the McNemar test for a difference between matched proportions and pmcn > 0.05 indicates that the sensitivity
or specificity of the INNO-LiPA assay are not significantly different from that of the HC2. b p for the test for
non-inferiority. A sensitivity threshold of at least 90% and a specificity threshold of at least 98% relative to that
of the HC2 were applied in a non-inferiority score test. pn.inf < 0.05 means that the sensitivity or specificity of the
INNO-LiPa is not significantly lower than that of the HC2.
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2.2. Genotyping Agreement between INNO-LiPA and Linear Array
In the total study population, concordance between INNO-LiPA and Linear Array was assessed at
type-specific level and overall for 13 hrHPV types (Table 4). Overall concordance of the two assays for
13 hrHPV types was 93.0% and the corresponding κ value was 0.805 (95% CI, 0.757–0.0854), indicating
excellent agreement between INNO-LiPA and Linear Array. Similarly, the level of agreement was
also excellent for detection of HPV16, HPV18, HPV35, HPV45, HPV58 and HPV59. However, for the
identification of other individual types, level of agreement ranged from good to poor between the
two assays (Table 4). In addition, INNO-LiPA detected more positive cases than Linear Array for all
individual types common to both assays.
Table 4. Agreement (concordance and κ values) between the INNO-LiPA and the Linear Array
for overall hrHPV positivity and for 29 individual HPV types common to both assays in the total
study population.
HPV Type I+/L+ I+/L− I−/L+ I−/L− Concordance κ (95% CI) pmcn a
13 hrHPV b 318 103 9 1166 93.0% 0.805 (0.757–0.854) <0.001
HPV16 112 16 2 1466 99.0% 0.920 (0.871–0.969) 0.001
HPV18 31 6 3 1556 99.4% 0.870 (0.822–0.920) 0.3173
HPV31 68 50 1 1417 96.8% 0.712 (0.664–0.759) <0.001
HPV33 24 13 1 1558 99.2% 0.770 (0.722–0.818) 0.0013
HPV35 5 0 0 1591 100.0% 1.000 (0.951–1.049) 1.0000
HPV39 15 9 2 1570 99.1% 0.728 (0.680–0.777) 0.0348
HPV45 14 6 0 1576 99.6% 0.822 (0.774–0.870) 0.0143
HPV51 33 16 1 1546 98.9% 0.790 (0.742–0.838) <0.001
HPV52 30 26 2 1538 94.6% 0.674 (0.633–0.714) 0.8840
HPV56 16 9 7 1564 99.0% 0.662 (0.613–0.712) 0.6171
HPV58 19 5 0 1572 99.7% 0.882 (0.833–0.931) 0.0253
HPV59 17 2 2 1575 99.8% 0.894 (0.845–0.943) 1.0000
HPV68 7 26 0 1563 98.4% 0.345 (0.308–0.382) <0.001
HPV26 c 0 0 0 1596 100.0% - 1.0000
HPV53 43 23 1 1529 98.5% 0.774 (0.726–0.822) <0.001
HPV66 29 16 1 1550 98.9% 0.768 (0.720–0.816) <0.001
HPV70 11 10 0 1575 99.4% 0.685 (0.638–0.731) 0.0016
HPV73 19 7 2 1570 99.4% 0.788 (0.739–0.837) 0.0956
HPV82 5 4 1 1586 99.7% 0.665 (0.617–0.713) 0.1797
HPV06 7 14 1 1574 99.1% 0.479 (0.435–0.523) 0.0008
HPV11 2 3 0 1591 99.8% 0.571 (0.526–0.615) 0.0833
HPV40 1 4 0 1591 99.8% 0.333 (0.296–0.369) 0.0455
HPV42 3 5 9 1579 99.1% 0.296 (0.248–0.344) 0.2850
HPV54 10 14 12 1560 98.4% 0.427 (0.378–0.476) 0.6949
HPV61 16 17 6 1557 98.6% 0.575 (0.527–0.623) 0.0218
HPV62 15 12 9 1560 98.7% 0.582 (0.533–0.632) 0.5127
HPV67 3 5 1 1587 99.6% 0.498 (0.452–0.543) 0.1025
HPV81 3 3 1 1589 99.8% 0.599 (0.551–0.647) 0.3173
HPV83 0 6 3 1587 99.4% −0.003 (−0.049–0.044) 0.3173
I+ = INNO-LiPA positive; I− = INNO-LiPA negative; L+ = Linear Array positive; L− = Linear Array negative.
Color legend (adapted from Landis and Koch for the levels of agreement [25]): dark green (1.00 ≥ κ >0.80):
excellent; light green (0.80 ≥ κ > 0.60): good; yellow (0.60 ≥ κ > 0.40): moderate; orange (0.40 ≥ κ > 0.20): fair;
red (0.20 ≥ κ > 0.00): poor. a p for the McNemar test for a difference between matched proportions and pmcn < 0.05
indicates that the HPV positivity detected by INNO-LiPA is significantly different from that of the Linear Array.
b 13 hrHPV types: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58,
HPV59 and HPV68. c No HPV26 positive cases detected by both assays, κ value not applicable.
3. Discussion
The INNO-LiPA provides full genotyping capability for 32 HPV types. For the purpose of this
study, INNO-LiPA was considered positive if at least one of the 13 hrHPV types targeted by HC2
was detected.
To the best of our knowledge, the INNO-LiPA has not been validated previously according to the
international guidelines for evaluation of new HPV tests in primary cervical cancer screening settings.
Here, we present the first study to evaluate the clinical performance of the INNO-LiPA compared
to HC2 using samples from the VALGENT-3 panel. In the whole study population, the INNO-LiPA
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showed a sensitivity for the detection of CIN2+ and CIN3+ of 97% and 99%, respectively, which was
similar to HC2. However, the clinical specificity for ≤CIN1 was only 85%, which was 5% (95% CI,
3–7%) lower than the comparator test.
INNO-LiPA is a SPF10 PCR that targets a short highly conserved region in the L1 gene [21,26].
The small size of the amplicon makes the test analytically very sensitive. However, at the same time,
discrimination of the individual types is challenging and complex and it is therefore not so surprising
that the clinical specificity is lower compared to HPV tests targeting longer DNA sequences [27].
The small size of the amplicon makes INNO-LiPA particularly useful for testing of archived cell
preparations or formaline-fixed-paraffin-embedded tissue blocks stored over long periods where parts
of the viral genome can be fragmented [28].
INNO-LiPA provides for each HPV type a qualitative output, which is translated into a
positive/negative result. The appreciation of presence or absence of blue lines is not quantifiable.
Therefore, adaptation of the cut-off, which may allow a more optimal balance between clinical
sensitivity and specificity, is in case of INNO-LiPA not possible.
Excellent analytical agreement between INNO-LiPA and Linear Array was observed for 13 hrHPV
types overall, HPV16, HPV18, HPV35, HPV45, HPV58 and HPV59. In addition, INNO-LiPA detected
more positive cases than Linear Array for all individual HPV types that are common to both assays,
with a positivity rate of hrHPV determined by INNO-LiPA statistically significantly higher than that
determined by Linear Array (pmcn < 0.001) in the total study population. The significant difference
of positivity rate for hrHPV with these two genotyping methods is consistent with the tests’ clinical
performances with regard to relative specificity compared to HC2.
In conclusion, in our study, INNO-LiPA exhibits lower clinical specificity; however, this is most
likely due to detection of HPV infections with low concentrations and therefore can play an important
role in evaluation of viral infection outcomes of vaccination trials and in monitoring the impact of
HPV vaccination. Moreover, INNO-LiPA may be useful in epidemiological studies to investigate the
prevalence and distribution of HPV types and in studies of the natural history of HPV infection at the
type-specific level.
4. Materials and Methods
4.1. Clinical Specimens
The VALGENT framework is designed to assess the comparative analytical and clinical
performance of HPV tests that offer limited to full genotyping capability [29]. VALGENT is
iterative, using specimens collected in different countries. The first two VALGENT panels have
been completed, using samples collected from Belgium [30–32] and Scotland [33–36]. The third
study panel (VALGENT-3) was collated in Slovenia as previously described [11,23,24]. Briefly,
1300 consecutive cervical samples were collected from women who participated in the organised
Slovenian national cervical cancer screening program between December 2009 and August 2010
(screening population). The study panel was enriched with 300 cytologically abnormal specimens
collected between January 2014 and May 2015 (enrichment population). As required in the VALGENT
protocol [29], the enrichment population included 100 women with atypical squamous cervical cells
of undetermined significance (ASC-US), 100 women with low-grade squamous intraepithelial lesion
(LSIL) and 100 women with high-grade squamous intraepithelial lesion (HSIL).
The sample collection, aliquoting procedure and storage details have been described in detail in
previous VALGENT-3 manuscripts [23,24]. Briefly, in July 2016, Ghent University (Ghent Belgium)
received 1600 samples of extracted DNA. DNA was extracted from original samples collected into
ThinPrep PreservCyt solution (Hologic, Marlborough, MA, USA). Prior to DNA extraction, 1 mL
aliquot of original ThinPrep sample was centrifuged at 13,000× g for 15 m with supernatant being
discarded and cellular pellet resuspended in 200 µL PBS buffer. DNA extraction was performed using
QIAamp MinElute Media Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions.
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Bound DNA was finally eluted with 50 µL of ATE buffer and stored at −70 ◦C prior to further testing.
According to the manufacturer’s instructions, we have used 10 µL of extracted DNA for INNO-LiPA
testing. Similarly, from the second aliquot of original ThinPrep DNA was extracted for Linear Array
testing, where 50 µL of extracted DNA was used for further testing.
4.2. HPV Testing
4.2.1. INNO-LiPA HPV Genotyping Extra II
The INNO-LiPA is a line probe assay based on the principle of reverse hybridization for qualitative
detection and identification of 32 different HPV types, including 13 hrHPV (HPV16, HPV18, HPV31,
HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59 and HPV68), 6 possible
hrHPV (HPV26, HPV53, HPV66, HPV70, HPV73 and HPV82), 9 low-risk HPV (HPV6, HPV11, HPV40,
HPV42, HPV43, HPV44, HPV54, HPV61 and HPV81) plus 4 other HPV genotypes (HPV62, HPV67,
HPV83 and HPV89). INNO-LiPA uses the biotinylated consensus primers (SPF10) to amplify a 65-bp
region within the L1 region of multiple alpha HPV types. The resulting biotinylated amplicons are
then denatured and hybridized with specific oligonucleotide probes. A primer set for the amplification
of the human HLA-DPB1 gene is included to monitor sample quality and extraction. The INNO-LiPA
assay (sample incubation, stringent wash and color development) was performed fully automated
using the AutoBlot 3000H (Bio-Rad Laboratories Inc., Hercules, CA, USA). Interpretation of the
developed strips was done by scanning and automated interpretation using with the LiRAS for LiPA
HPV software (Version 3.01, Fujirebio Europe, Ghent, Belgium). The test was performed in accordance
with the manufacturer’s instructions.
4.2.2. HC2
HC2 detects 13 hrHPV types (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51,
HPV52, HPV56, HPV58, HPV59, and HPV68) and is accepted as a standard comparator test for the
clinical validation of hrHPV DNA assays that may be used for primary cervical cancer screening [15].
For the purpose of the present study, hrHPV positivity for INNO-LiPA was defined as the presence of
one or more of the 13 hrHPV targeted by HC2.
4.2.3. Linear Array
The Linear Array is an HPV test with full genotyping capacity, which detects 37 high- and low-risk
HPV types (HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV40, HPV42,
HPV44, HPV45, HPV51, HPV52, HPV53, HPV54, HPV56, HPV58, HPV59, HPV61, HPV62, HPV64,
HPV66, HPV67, HPV68, HPV69, HPV70, HPV71, HPV72, HPV73, HPV81, HPV82, HPV83, HPV84,
HPV89, and IS39) that is frequently used in virological and epidemiological research. In the present
study, Linear Array is used as a comparator test to evaluate the analytical genotyping accuracy of
the INNO-LiPA.
4.3. Clinical Outcome and INNO-LiPA Performance Assessment
As described in previous VALGENT-3 reports [23,24], cytological assessment and referral of
patients with abnormal cytology results to colposcopy were done according to the Slovenian national
screening guidelines [37], which are in agreement with European guidelines [38]. Colposcopy-directed
punch biopsies were obtained from suspicious areas for final histopathological assessment.
Women with histologically confirmed CIN2+ results were considered as diseased subjects. Due to
the fact that women with normal cytological results of negative for intraepithelial lesion or malignancy
(NILM) were not referred to colposcopy verification in our study, we considered them as subjects
without disease only if they had two or more consecutive NILM cytological results (at enrolment and
at subsequent screening between 12 to 48 months later). We used this group of women to compute the
clinical specificity for ≤CIN1.
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The clinical sensitivity and specificity of the INNO-LiPA for CIN2+ and CIN3+ were calculated.
We compared the clinical accuracy of INNO-LiPA to HC2 for CIN2+ and CIN3+, using non-inferiority
statistics with a relative sensitivity threshold of 90% and a relative specificity threshold of 98% [39].
The McNemar statistic was used in order to compare the differences between matched proportions [40].
For both statistics, the level of significance was set at 0.05. All analyses were performed using STATA
version 14 (Manufacturer, College Station, TX, USA).
Separate and consensus genotyping agreement for the types common to INNO-LiPA and Linear
Array was assessed using κ [41] and McNemar statistics [40]. κ values from 0.0 to 0.20, 0.21 to
0.40, 0.41 to 0.60, 0.61 to 0.80 and 0.81 to 1.0 indicate poor, fair, moderate, good and excellent level
of agreement between two assays. A McNemar p-value of <0.05 indicates significant discordance
between genotyping results determined by the two assays.
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